Categories
Change Password!
Reset Password!
Coordinated care from multiple specialities is essential for better management of patients with both diabetes and heart conditions.
Given the alarming intersection of cardiovascular disease (CVD) and diabetes, the European Society of Cardiology (ESC) has released new clinical guidelines for managing CVD in people with diabetes mellitus, addressing a growing global health challenge. Throughout the world, cardiovascular conditions are a leading cause of death, accounting for nearly 18 million fatalities annually, with diabetes compounding the risk as per World Health Organization (WHO).
Studies have shown that roughly 20% of cardiovascular deaths are linked to elevated blood sugar levels, and CVDs are the primary cause of death in those with type 2 diabetes. Data from Russia's Federal Register of Diabetes 2022 revealed that chronic heart failure was the leading cause of death (24.2%) of type 2 diabetics, followed by acute heart failure (13.1%), cerebral vascular events (10%), and heart attack/myocardial infarction (3.7%).
This growing overlap has highlighted the necessity for more cooperation between cardiologists and endocrinologists, scintillating talks about the emergence of a new subspeciality: diabetocardiology. With the global diabetic population expected to surge to 783 million, timely intervention is of utmost importance.
The 2023 ESC guidelines contemplated this reality, offering a broad, interdisciplinary approach to treatment. New research on cardiovascular benefits from specific hypoglycemic medications, including SGLT2 inhibitors, GLP-1 receptor agonists, and the non-steroidal mineralocorticoid receptor antagonist finerenone, further reinforced the need for a unified treatment strategy.
Problemy ėndokrinologii (Problems of Endocrinology)
Summary of the 2023 European Society of Cardiology clinical guidelines on the management of cardiovascular disease in patients with diabetes mellitus
A D Erlikh et al.
Comments (0)